var data={"name":"Chemotherapeutic agents","type":"SECTION","numTopics":"11,000","numSpecialties":"over 22","sections":[{"name":"Chemotherapy regimens","type":"SUBSECTION","items":[{"name":"Treatment protocols for anal cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-anal-cancer"},{"name":"Treatment protocols for bladder cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-bladder-cancer"},{"name":"Treatment protocols for breast cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-breast-cancer"},{"name":"Treatment protocols for castration-resistant prostate cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-castration-resistant-prostate-cancer"},{"name":"Treatment protocols for esophagogastric cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-esophagogastric-cancer"},{"name":"Treatment protocols for germ cell tumors","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-germ-cell-tumors"},{"name":"Treatment protocols for gynecologic malignancies","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-gynecologic-malignancies"},{"name":"Treatment protocols for hepatobiliary cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-hepatobiliary-cancer"},{"name":"Treatment protocols for lymphoma","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-lymphoma"},{"name":"Treatment protocols for multiple myeloma","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-multiple-myeloma"},{"name":"Treatment protocols for non-small cell lung cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-non-small-cell-lung-cancer"},{"name":"Treatment protocols for pancreatic cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-pancreatic-cancer"},{"name":"Treatment protocols for renal cell cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-renal-cell-cancer"},{"name":"Treatment protocols for small and large bowel cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-small-and-large-bowel-cancer"},{"name":"Treatment protocols for small-cell carcinoma of the lung","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-small-cell-carcinoma-of-the-lung"},{"name":"Treatment protocols for soft tissue and bone sarcoma","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-soft-tissue-and-bone-sarcoma"},{"name":"Treatment protocols for squamous cell carcinoma of the head and neck","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-protocols-for-squamous-cell-carcinoma-of-the-head-and-neck"}]},{"name":"Side effects","type":"SUBSECTION","items":[{"name":"Autoimmune complications following purine analog therapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=autoimmune-complications-following-purine-analog-therapy"},{"name":"Bleomycin-induced lung injury","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=bleomycin-induced-lung-injury"},{"name":"Busulfan-induced pulmonary injury","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=busulfan-induced-pulmonary-injury"},{"name":"Cancer-related fatigue: Prevalence, screening and clinical assessment","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cancer-related-fatigue-prevalence-screening-and-clinical-assessment"},{"name":"Cancer-related fatigue: Treatment","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cancer-related-fatigue-treatment"},{"name":"Cardiotoxicity of nonanthracycline cancer chemotherapy agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cardiotoxicity-of-nonanthracycline-cancer-chemotherapy-agents"},{"name":"Cardiotoxicity of trastuzumab and other HER2-targeted agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents"},{"name":"Chemotherapy hepatotoxicity and dose modification in patients with liver disease","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease"},{"name":"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents"},{"name":"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents"},{"name":"Chemotherapy-induced alopecia","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=chemotherapy-induced-alopecia"},{"name":"Chlorambucil-induced pulmonary injury","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=chlorambucil-induced-pulmonary-injury"},{"name":"Cisplatin nephrotoxicity","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cisplatin-nephrotoxicity"},{"name":"Common terminology criteria for adverse events","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=common-terminology-criteria-for-adverse-events"},{"name":"Crystal-induced acute kidney injury (acute renal failure)","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure"},{"name":"Cutaneous side effects of conventional chemotherapy agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents"},{"name":"Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy"},{"name":"Cyclophosphamide pulmonary toxicity","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cyclophosphamide-pulmonary-toxicity"},{"name":"Cystitis in patients with cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=cystitis-in-patients-with-cancer"},{"name":"Differentiation (retinoic acid) syndrome","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=differentiation-retinoic-acid-syndrome"},{"name":"Drug-induced thrombotic microangiopathy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=drug-induced-thrombotic-microangiopathy"},{"name":"Effects of cytotoxic agents on gonadal function in adult men","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=effects-of-cytotoxic-agents-on-gonadal-function-in-adult-men"},{"name":"Enterotoxicity of chemotherapeutic agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=enterotoxicity-of-chemotherapeutic-agents"},{"name":"Extravasation injury from chemotherapy and other non-antineoplastic vesicants","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=extravasation-injury-from-chemotherapy-and-other-non-antineoplastic-vesicants"},{"name":"General toxicity of cyclophosphamide in rheumatic diseases","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=general-toxicity-of-cyclophosphamide-in-rheumatic-diseases"},{"name":"Heavy or irregular uterine bleeding during chemotherapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=heavy-or-irregular-uterine-bleeding-during-chemotherapy"},{"name":"Hematologic complications of malignancy: Anemia and bleeding","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=hematologic-complications-of-malignancy-anemia-and-bleeding"},{"name":"Infusion reactions to systemic chemotherapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=infusion-reactions-to-systemic-chemotherapy"},{"name":"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy"},{"name":"Medication-related osteonecrosis of the jaw in patients with cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=medication-related-osteonecrosis-of-the-jaw-in-patients-with-cancer"},{"name":"Methotrexate-induced lung injury","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=methotrexate-induced-lung-injury"},{"name":"Mitomycin-C pulmonary toxicity","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=mitomycin-c-pulmonary-toxicity"},{"name":"Neurologic complications of cancer treatment with biologic agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=neurologic-complications-of-cancer-treatment-with-biologic-agents"},{"name":"Nitrosourea-induced pulmonary injury","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=nitrosourea-induced-pulmonary-injury"},{"name":"Oral toxicity associated with chemotherapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=oral-toxicity-associated-with-chemotherapy"},{"name":"Ovarian failure due to anticancer drugs and radiation","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=ovarian-failure-due-to-anticancer-drugs-and-radiation"},{"name":"Overview of neurologic complications of non-platinum cancer chemotherapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy"},{"name":"Overview of neurologic complications of platinum-based chemotherapy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=overview-of-neurologic-complications-of-platinum-based-chemotherapy"},{"name":"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting"},{"name":"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-adults"},{"name":"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults"},{"name":"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-cytotoxic-agents"},{"name":"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-molecularly-targeted-agents"},{"name":"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment"},{"name":"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=risks-of-therapy-with-bone-antiresorptive-agents-in-patients-with-advanced-malignancy"},{"name":"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer"},{"name":"Systemic chemotherapy for cancer in elderly persons","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=systemic-chemotherapy-for-cancer-in-elderly-persons"},{"name":"Taxane-induced pulmonary toxicity","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=taxane-induced-pulmonary-toxicity"},{"name":"Therapeutic use and toxicity of high-dose methotrexate","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate"},{"name":"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects"},{"name":"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects"},{"name":"Treatment-related toxicity in men with testicular germ cell tumors","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=treatment-related-toxicity-in-men-with-testicular-germ-cell-tumors"},{"name":"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors"},{"name":"Tumor lysis syndrome: Prevention and treatment","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=tumor-lysis-syndrome-prevention-and-treatment"},{"name":"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation","type":"TOPIC","languageCode":"EN","url":"topic.htm?path=use-of-granulocyte-colony-stimulating-factors-in-adult-patients-with-chemotherapy-induced-neutropenia-and-conditions-other-than-acute-leukemia-myelodysplastic-syndrome-and-hematopoietic-cell-transplantation"}]}]}